



# Biotech Daily

Tuesday November 5, 2013

*Daily news on ASX-listed biotechnology companies*

**\* ASX UP, BIOTECH DOWN: PATRYS UP 17%, USCOM DOWN 14%**

**\* IMUGENE COMPLETES FIRST \$850k TRANCHE OF \$2.5m PLACEMENT**

**\* BIONICHE APPOINTS DR MICHAEL BERENDT CEO**

## MARKET REPORT

The Australian stock market climbed 0.77 percent on the Melbourne Cup Day holiday Tuesday November 5, 2013 with the S&P ASX 200 up 41.5 points to 5,432.0 points.

Eleven of the Biotech Daily Top 40 stocks were up, 20 fell, eight traded unchanged and one was untraded.

Patrys was the best, up 0.5 cents or 16.7 percent to 3.5 cents, with 12.4 million shares traded, followed by Allied Health up 11.5 percent to 14.5 cents with 14.6 million shares traded and Tissue Therapies up 11.4 percent to 24.5 cents with 308,552 shares traded.

Living Cell climbed 9.6 percent; Prana was up 6.7 percent; Circadian was up 4.1 percent; Alchemia and Benitec rose more than two percent; with Anteo, Medical Developments, Osprey and Resmed up more than one percent.

Uscom led the falls, down 2.5 cents or 13.9 percent to 15.5 cents with 72,387 shares traded.

Phylogica lost 9.1 percent; Psivida fell 7.4 percent; Bionomics was down 6.4 percent; Ellex and Optiscan were down five percent or more; Avita, Nanosonics and Neuren fell more than four percent; GI Dynamics and IDT were down more than three percent; Cellmid, Clinuvel, Mesoblast, Reva and Starpharma shed more than two percent; Genetic Technologies QRX and Universal Biosensors were down more than one percent; with Cochlear, CSL and Sirtex down by less than one percent.

## IMUGENE

Imugene says it has issued the first tranche of 85,000,000 placement shares raising \$850,000 of the total \$2,500,000 at one cent a share (BD: Oct 23, 2103).

Last month Imugene said it would acquire Biolife Science Qld for its HER-Vaxx peptide-based immunotherapy for HER-2/neu associated tumors, for 300,000,000 shares and the \$2.5 million placement was partly to fund the Biolife acquisition as well as continuing activities.

Today, Imugene said that the remaining 165,000,000 shares would be issued subject to shareholder approval at an extraordinary general meeting.

Imugene fell 0.1 cents or 4.55 percent to 2.1 cents.

## BIONICHE LIFE SCIENCES

Bioniche says Dr Michael Berendt has been appointed as its chief executive officer, effective immediately.

Bioniche said that Dr Berendt replaced founder and former executive chairman Graeme McRae, who would continue as 'chairman emeritus'.

The company said that Dr Berendt had a background in the life sciences sector, most recently serving as chief executive officer of the Montréal, Québec-based Aegea Therapeutics and had held positions in the US research departments of Pfizer and Bayer Corp, before becoming life sciences managing director of AEA Investors.

Bioniche said that Dr Berendt held a Bachelor of Science from Ohio Dominican University, a Master of Science from Miami University and a Doctorate of Philosophy from Drexel University.

Bioniche was untraded at 38 cents.